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Fighting pathogens and maintaining tissue homeostasis are prerequisites for survival. Both of these func-
tions are upheld by the immune system, though the latter is often overlooked in the context of the CNS.
The mere presence of immune cells in the CNS was long considered a hallmark of pathology, but this view
has been recently challenged by studies demonstrating that immunological signaling can confer pivotal neu-
roprotective effects on the injured CNS. In this review, we describe the temporal sequence of immunological
events that follow CNS injury. Beginning with immediate changes at the injury site, including death of neural
cells and release of damage-associated molecular patterns (DAMPs), and progressing through innate and
adaptive immune responses, we describe the cascade of inflammatory mediators and the implications of
their post-injury effects. We conclude by proposing a revised interpretation of immune privilege in the brain,
which takes beneficial neuro-immune communications into account.Neuro-immune Communication
The immune system exists pervasively throughout the body, de-
fending against invaders, supporting tissue healing, and main-
taining homeostasis. Though clearly important in the periphery,
its role in the central nervous system (CNS) is complicated by
several unique mechanisms. The unperturbed CNS is separated
from the periphery by the blood-brain barrier (BBB), a selectively
permeable barrier that prevents immune cell infiltration and free
passage of bloodborne molecules into the healthy brain (Broad-
well and Sofroniew, 1993; Bush et al., 1999; Habgood et al.,
2007; Muldoon et al., 2013). Furthermore, early experiments by
Peter Medawar and others demonstrated that foreign tissue
grafted into the CNS elicits a delayed immune response (Meda-
war, 1948). These observations paved the way for the concept of
CNS ‘‘immune privilege,’’ that the brain was privileged from
normal immune surveillance. Indeed, in the healthy state, no pe-
ripheral immune cells are detectable in the CNS parenchyma,
although resident microglia are found throughout the brain,
and the meningeal spaces are highly populated by various im-
mune cells (Derecki et al., 2010; Kivisa¨kk et al., 2009; Shechter
et al., 2013; Louveau et al., 2015).
The nature of neuroimmune interactions is controversial, with
various factors, including the concept of immune privilege, the
existence of the BBB, and the observation that excessive auto-
immune CNS inflammation drives pathology in multiple sclerosis
(Ousman et al., 2007; Steinman, 2014), contributing to the notion
that the activity of the peripheral immune system is harmful to the
CNS and does not support its function. This was the prevailing
dogma for decades, but over the past few years, it has been
increasingly challenged. Emerging data suggest that the periph-
eral immune system indeed participates in the maintenance of
homeostatic brain functions, with reports showing key neuroim-mune interactions regulating adult neurogenesis, learning
behavior, the ability to cope with psychological stress, and other
brain functions (reviewed in Kipnis et al., 2012). Persuasive evi-
dence indicates, moreover, that the immune system also sup-
ports the injured CNS (Raposo and Schwartz, 2014; Walsh
et al., 2014b), offers protection against CNS infections (Norose
et al., 2011), and plays a beneficial role in pathological states
such as Alzheimer’s disease (Hickman and El Khoury, 2010),
glaucoma (Schwartz and London, 2009), and several other
neurological disorders (Derecki et al., 2012; Frenkel et al.,
2003; Yong and Rivest, 2009).
The role of the immune system in the context of CNS injury
has been particularly well studied. Injury to the CNS elicits a
distinct inflammatory cascade that begins with cell death and
progresses through multiple molecular and cellular phases
(Figure 1). This is similar to the inflammatory cascade described
in injuries to peripheral tissues, where the immune system, if well
controlled, is generally thought to support healing. However, the
consequences of the immune response to CNS injury remain
controversial, with some groups reporting aspects of it to be
beneficial (Huang et al., 1999; Kurimoto et al., 2013; Shechter
et al., 2009; Walsh et al., 2015; Yin et al., 2006), while others
describe it as destructive (Evans et al., 2014; Gonzalez et al.,
2007; Kroner et al., 2014; Popovich et al., 1999; Yawata et al.,
2008).
DAMPs, PAMPs, and Alarmins—Dialing 911 for
Tissue Injury
The immune system has evolved to respond not only to patho-
gens but also to virtually any insult that threatens homeostasis,
including trauma, cellular and metabolic dysfunction, ischemia-
reperfusion injury, or environmental irritants. InflammationoccursNeuron 87, July 1, 2015 ª2015 Elsevier Inc. 47
Figure 1. Kinetics of the Molecular and
Cellular Immune Response to CNS Injury
(A) The phases of molecular and cellular inflam-
mation after CNS injury. DAMPs such as IL-33,
HMGB1, and ATP are released immediately
following CNS injury. The inflammasome is acti-
vated soon after and produces mature IL-1b and
IL-18. Neutrophils arrive hours after injury and stay
for several days, while monocytes begin infiltrating
within the first day and remain present. Lympho-
cytes begin to arrive days to weeks post-injury.
(B) Specific inflammatory molecules active at
each time post-injury are listed. GDNF, glial cell
line-derived neurotrophic factor; BDNF, brain-
derived neurotrophic factor; ROS, reactive oxygen
species.
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entails a stereotypical cascade of recruitment of neutrophils,
monocytes, and lymphocytes to the site of injury and their activa-
tion there. This recruitment of peripheral immune cells is pre-
ceded by an immediate response from local cells that sense
danger and ‘‘sound the alarm’’ by producing chemokines and
cytokines. Immune activation is a tightly controlled process,
and with good reason; an inappropriate response can result in
devastating damage to CNS tissue and the development of auto-
immune disease, while the inability to mount a proper immune
response when needed can have fatal consequences.
How do cells discern between health and injury—sounding the
alarm and initiating an immune response only when necessary?
A classical explanation is that the immune system discriminates
between ‘‘self’’ and ‘‘non-self’’ (Janeway, 1992), using special-
ized T- and B-cell receptors that respond to foreign antigens
and only mounting a response to anything deemed ‘‘non-self.’’
This explanation is clearly not satisfactory as, in the context of
sterile inflammation, there would be no ‘‘non-self’’ antigens to
trigger a response. An alternate model for how the immune sys-
tem chooses whether or not to respond, coined by Matzinger as
the ‘‘danger theory,’’ states that, rather than responding to self
versus non-self, the immune system initially responds to danger
or damage signals that can be either pathogen- or self-derived
(Matzinger, 2001, 2002). Thus, damage-associated molecular
patterns (DAMPs) can be either endogenously derived ‘‘alar-
mins’’ or exogenous ‘‘pathogen-associated molecular patterns’’
(PAMPs) (Bianchi, 2007). PAMPs and alarmins represent the
presence of pathogen or tissue damage, respectively, and are
detected by pattern recognition receptors (PRRs) to initiate
and amplify an immune response (Bianchi, 2007). Many types
of DAMPs are expressed in the healthy CNS and are released
after injury to initiate inflammation.
DAMPs encompass an extremely diverse class of molecules,
ranging from bacterial lipids or peptides to endogenous proteins,
nucleic acids, andmetabolites. Though diverse, all DAMPs share48 Neuron 87, July 1, 2015 ª2015 Elsevier Inc.the characteristic of promoting immune
activation in response to damage. A
well-characterized group of DAMPs con-
sists of intracellular proteins that are
expressed at a basal level within a cell
and are released after cell injury. Exam-
ples of endogenous protein DAMPs areinterleukin (IL)-1a (Eigenbrod et al., 2008), IL-33 (Schmitz et al.,
2005), high-mobility group protein B1 (HMGB1) (Scaffidi et al.,
2002), and the S100 class of proteins (Zitvogel et al., 2010), all
of which bind specific receptors and promote initiation of inflam-
mation after injury. It is interesting that many endogenous protein
DAMPs (including IL-33, HMGB1, and IL-1a) are concentrated in
the nucleus, where they presumably perform non-alarmin func-
tions, though these are generally not fully understood.
A second class of DAMPs comprises nucleic acids and nucle-
otide derivatives. Among the best described of these is mito-
chondrial DNA (mtDNA). While eukaryotic DNA has a character-
istic methylation pattern that renders it non-immunogenic,
mtDNA more closely resembles prokaryotic DNA (Zhang et al.,
2010) and is capable of stimulating some of the same pathways
as those evolved for sensing pathogenic bacteria. mtDNA
becomes more immunogenic when oxidized, a condition that
occurs under severe cell stress and endows it with greater spec-
ificity for damaged cells (Ding et al., 2013). ATP and uric acid are
two purine nucleotide derivatives that also have well-studied
alarmin properties. ATP is amultifunctional molecule, well known
for storing energy and as a signaling molecule that can mediate
diverse effects. Abundant ATP in the extracellular space is also
detected by the immune system as a DAMP. However, another
nucleotide-derivedDAMP is uric acid, ametabolite that is soluble
intracellularly, but upon exposure to the extracellular environ-
ment precipitates and forms crystals of monosodium urate.
Both uric acid and ATP can activate the inflammasome cascade
(described in detail later) and, through it, promote the production
of several inflammatory chemokines and cytokines (Kim et al.,
2015; Lee et al., 2012).
DAMPs alert the immune response to tissue damage, and
although sterile inflammation can promote wound healing, it
can also potentiate disease. In recent years, non-communicable
chronic diseases that are potentiated by dysregulated sterile
inflammation have replaced infectious diseases as the preemi-
nent threat to human health (GBD 2013 Mortality and Causes
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aberrant tissue damage, indeed, plays pivotal roles in the path-
ogenesis of various prevalent human diseases, including athero-
sclerosis, type 2 diabetes, obesity, and some neurodegenerative
diseases (Lukens et al., 2012b).
PRRs Alert the Immune System to Pathogens and
Cell Damage
PRRs represent a large group of receptors with an even larger
repertoire of potential ligands. There are numerous PRR fam-
ilies, including the Toll-like receptors (TLRs), NOD-like recep-
tors (NLRs), AIM2-like receptors (ALRs), RIG-I-like receptors
(RLRs), and C-type lectin receptors (CLRs). Each of these cat-
egories has multiple representatives and species differences;
for example, humans have 10 TLRs and 22 NLRs, whereas
mice have 12 TLRs and 34 NLRs (Bryant and Monie, 2012).
Many of these PRRs, in turn, have multiple ligands, often a
combination of PAMPs and DAMPs. One example is the
TLR4, well known for binding to lipopolysaccharide (LPS)
found on the outer core of Gram-negative bacteria, which
also binds to a wide array of endogenous DAMPs, such as
HMGB1 (Erridge, 2010).
Despite their diversity of receptors and ligands, specific clas-
ses of PRRs tend to induce similar intracellular signaling cas-
cades. For example, TLRs are found on intra- or extracellular
membranes and typically signal through MyD88 and/or TRIF in
response to protein or nucleic acid DAMPs (Erridge, 2010).
NLRs are cytoplasmic PRRs and often signal through the inflam-
masome protein complex (Latz et al., 2013). RLRs, cytoplasmic
PRRs that recognize double-stranded RNA, play an important
role in host defense against viruses by recruiting the adaptor pro-
tein IPS1 and signaling through the interferon (IFN) regulatory
factor (IRF) family and necrosis factor kB (NF-kB) transcription
factors (Loo and Gale, 2011). ALRs are also found in the cytosol
and initiate inflammasome activation following recognition of
cytosolic double-stranded DNA (Ratsimandresy et al., 2013). A
final PRR is the receptor for advanced glycation endproducts
(RAGE). This receptor, found on the extracellular surface, was
originally described as a receptor that recognizes glycosylated
proteins and lipids, but was later found also to detect other pro-
teins such as S100B, amyloid-beta fibrils, and the alarmin
HMGB1 (Xie et al., 2013). RAGE couples with mDia1 and
Src to activate a myriad of signaling pathways that affect cell
survival, autophagy, cell motility, and inflammation (through
NF-kB) (reviewed in (Xie et al., 2013)).
CNS Injury
Millions of people suffer traumatic CNS injuries every year (Rut-
land-Brown et al., 2006). Although the results can be quite vari-
able, depending on the location and severity of trauma, CNS
injuries fail to regenerate over time and often lead to permanent
disability (Ruffolo et al., 1999). Traumatic spinal cord injury
(SCI), for example, results in at least some degree of paralysis
on discharge in over 99% of cases (National Spinal Cord Injury
Statistical Center, 2014). Coupled with this poor prognosis is a
dire lack of effective therapies. The only pharmacological treat-
ment currently approved for improvement of neurologic recovery
after SCI ismethylprednisone, a glucocorticoid with immunosup-pressive properties. Though this has been the standard care for
many years, evidence in support of its beneficial effects is limited
(Bracken, 2012), and its use is currently under debate (Lammer-
tse, 2013).
Why does the CNS not recover after injury? Neuroscientists
have been mystified by this question for decades, and as yet,
no single explanation can fully provide the answer. In general,
obstacles to recovery can be divided into two categories: bar-
riers to regeneration, either neuron intrinsic (Liu et al., 2011) or
neuron extrinsic (Fawcett et al., 2012); and secondary death—
the persistence, in the days and weeks after injury, of ongoing
progressive neuronal degeneration beyond the primary lesion
(Algattas and Huang, 2014; Yoles and Schwartz, 1998). Un-
treated or inadequately treated, these two major phenomena
are targeted by neuroregenerative and neuroprotective agents,
respectively, and represent the bulk of efforts in the quest for
effective therapies for CNS injury.
Cell Death after CNS Injury
As touched upon earlier, injury to the CNS is characterized by
two distinct phases of cell death. First, mechanical trauma at
the time of injury causes direct damage to neurons, glia, vascu-
lature, and meningeal cells, inducing necrotic death of neurons
and glia (Grossman et al., 2001). Then, over the following days
and weeks an ongoing process of secondary death leads to
increased lesion size and worsened outcome, primarily owing
to apoptotic cell death (Dusart and Schwab, 1994; Liu et al.,
1997; Lytle and Wrathall, 2007). The kinetics and relative contri-
bution of primary versus secondary death to total neuron loss
varies between injuries and depends, in particular, on the
severity of injury (Yoles and Schwartz, 1998). In the case of
crush injury to the spinal cord, most of the motor neurons
that suffered mechanical damage are lost in minutes to hours
after the injury (Fehlings et al., 2012). Similarly, the trauma is
rapidly followed by a primary wave of glial degeneration (Feh-
lings et al., 2012), where astrocytes undergo maximal loss
within 24 hr (Lytle and Wrathall, 2007) and CC1+ oligodendro-
cytes degenerate over the first post-injury week (Casha et al.,
2001). Secondary death of both neurons and glia is caused
by the combined effects of noxious stimuli from free radicals
generated after injury (Algattas and Huang, 2014; Carrico
et al., 2009); excitotoxicity owing to the release of glutamate
from neurons, microglia, and macrophages (Yawata et al.,
2008); swelling of injured tissue, causing its further crushing
within limited space (Bareyre et al., 1997); hypoxia and meta-
bolic dysfunction that results from impaired blood flow (a
switch from aerobic to anaerobic glycolysis among other
things) (Algattas and Huang, 2014); and aspects of inflamma-
tion (Loane and Byrnes, 2010).
Inflammation begins soon after injury and remains a prominent
force throughout its progression (Shechter and Schwartz, 2013).
In subsequent sections, we will discuss the molecular and
cellular inflammatory events that occur in the minutes, days,
and weeks after CNS injury. Particular attention will be focused
on the initiation of CNS inflammation and the implications of
immune-cell activity for injury outcome, with the goal of outlining
our current understanding of CNS inflammation and its beneficial
and detrimental effects.Neuron 87, July 1, 2015 ª2015 Elsevier Inc. 49
Figure 2. Necrotic Cell Death Causes the
Release Alarmins into the Extracellular
Space
Necrotic cell death releases peptide and nucleic
acid derivative alarmins that initiate inflammation.
IL-33 plays an important role in bringing mono-
cyte-derived macrophages into the CNS through
upregulation of astrocytic chemokine expression.
ATP promotes chemotaxis of neutrophils (through
its activation of the inflammasome) and is directly
chemotactic to microglial processes. ATP and uric
acid also activate the inflammasome, stimulating
the assembly of the cytosolic NLR, ASC, and
pro-caspase 1. Pro-caspase 1 is auto-cleaved to
mature caspase 1, which cleaves pro-IL-1b and
pro-IL-18 to active forms and IL-33 to an inactive
form. HMGB1 acts on TLR4 and RAGE receptors
and directly promotes inflammatory cytokine and
chemokine production. An important transcription
factor downstream of both receptors is NF-kB,
important in enhancing inflammation and cellular
infiltration, but the RAGE receptor has several
other downstream signaling pathways (not shown
here). IL-1a and uric acid (gray arrows) are
important inducers of immune responses in
response to tissue damage in the periphery;
however, their roles in response to CNS injury
remained poorly defined.
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Glial Activation
As discussed earlier, injury to peripheral tissues results in cell
death and the release of alarmins with subsequent induction of
inflammation (Chen and Nun˜ez, 2010). Which alarmins, if any,
initiate inflammation after CNS injury? Below we discuss three
alarmins—ATP, HMGB1, and IL-33—that have been shown to
act in the CNS (Figure 2).
ATP
ATP participates in many signaling events, both in physiological
and in pathological contexts (reviewed in Franke et al., 2012),
and its presence in the extracellular space does not always imply
cell damage. However, when released abundantly and in
conjunction with other DAMPs, ATP plays an important role in
initiating the immune response to CNS trauma. Release of ATP
generally promotes inflammation by inciting the inflammasome
activity of NLRP3, a cytoplasmic NLR (Di Virgilio, 2007). This acti-50 Neuron 87, July 1, 2015 ª2015 Elsevier Inc.vation results in production of the inflam-
matory cytokines IL-1b and IL-18, which
exert broad proinflammatory effects,
including induction of chemokine pro-
duction (Lukens et al., 2012b). ATP is a
potent stimulator of several chemokines,
including CCL3, produced by microglia
(Kataoka et al., 2009), and CCL2, pro-
duced by astrocytes (Panenka et al.,
2001). ATP signaling is particularly critical
for neutrophil recruitment, as transcranial
delivery (through diffusion across a
thinned skull) of a purine receptor antag-
onist can suppress neutrophil responses
following traumatic brain injury (TBI)
(Roth et al., 2014). Although the chemo-tactic effect of ATP on neutrophils can be direct (Chen et al.,
2006), the results in the TBI model were consistent with inflam-
masome inhibition (thus resulting in decreased neutrophil
chemotaxis) (McDonald et al., 2010). Microglial processes are
also highly sensitive to ATP, showing dramatic chemotaxis to
ATP gradients (Davalos et al., 2005). Two-photon in-vivo imaging
disclosed that within minutes microglia respond in an ATP-
dependent manner to cortical injury (Davalos et al., 2005; Nim-
merjahn et al., 2005). Interestingly, high extracellular ATP can
induce further release of ATP from astrocytes, and such ATP-
induced ATP release is an important mechanism for amplifying
its alarmin effects in both neutrophil and microglial chemotaxis
(Davalos et al., 2005; Roth et al., 2014).
HMGB1
HMGB1 is a ubiquitous nuclear protein that is expressed in virtu-
ally all cells of the CNS (Daston and Ratner, 1994; Enokido et al.,
2008; Gao et al., 2011; Tenenbaum et al., 2006). HMGB1 has
Neuron
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and disease. It is important, for instance, in zebrafish brain devel-
opment (Zhao et al., 2011) and continues to serve an archi-
tectural and maintenance role in the nucleus of adult cells
(Lange and Vasquez, 2009). After injury, however, extracellular
HMGB1 serves as a potent activator of inflammation (Chen
et al., 2011; Scaffidi et al., 2002). Once released, HMGB1 can
signal via both TLR4 and RAGE receptors to potentiate the
migration, proliferation, and differentiation of immune cells (De-
gryse et al., 2001).
In the CNS, HMGB1 strongly upregulates several chemokines
in astrocytes, including neutrophil chemoattractants such as
CXCL1, CXCL2, and CCL3, and T-cell chemoattractants such
as CX3CL1, CCL2, CCL5, and CCL20 (Pedrazzi et al., 2007).
HMGB1 has also been shown to potentiate post-traumatic
CNS damage that correlates with increased infiltration of neutro-
phils. Inhibition of HMGB1 by antibody-mediated neutralization
or by pharmacological blockers was found to lead to improved
recovery from both SCI (Zhai et al., 2012) and TBI (Gu et al.,
2014; Okuma et al., 2012). Furthermore, genetic ablation of the
RAGE receptor was reported to improve outcome in a mouse
model of SCI (Guo et al., 2014). Notably, HMGB1 has also
been found to be beneficial in promoting CNS repair in non-
mammalian organisms. For example, a gecko paralog of
HMGB1 was shown to signal via RAGE to oligodendrocytes to
coordinate myelination after CNS injury (Dong et al., 2013) and
to neurons to promote neurite outgrowth (Saleh et al., 2013).
HMGB1 also contributes to axonal regeneration and recovery
after spinal cord transection in a zebrafish model (Fang et al.,
2014). The opposing roles of HMGB1 described in different or-
ganisms may be less puzzling, however, given a recent study
demonstrating that paralogs of gecko HMGB1 have other func-
tions, unrelated to inflammation, that directly support remyelina-
tion and CNS regeneration in these animals (Dong et al., 2013).
IL-33
Like HMGB1, IL-33 is a nuclear alarmin that is widely expressed
inmany tissues, with the highest expression observed in the skin,
lung, brain, and spinal cord (Schmitz et al., 2005). In the nucleus,
IL-33 appears to participate in gene silencing through its associ-
ation with heterochromatin (Carriere et al., 2007), but this notion
has been contested by high-resolution imaging methodologies
showing that it actually associates with euchromatin (Kakkar
et al., 2012). The precise role of IL-33 in the nuclei of healthy cells
remains poorly characterized. Its functions are clearer, however,
after cellular injury. IL-33 is released after cellular necrosis
and acts through its specific receptor (IL-33R), a heterodimer
of ST2 and the IL-1-receptor-associated protein (IL-1RAP), to
initiate inflammation in multiple cell types.
The IL-33R signals through MyD88, the adaptor protein also
used by most TLRs and the IL-1 receptor, and similarly results
in activation ofNF-kBandMAPkinase signaling. Specific expres-
sion of the IL-33R by certain immune cells links IL-33 to type 2
immune responses. These responses, typically found in asthma,
allergy, and anti-parasite immunity, are associated with mast
cells, type 2 innate lymphocytes (ILC2s), and type 2 helper
T cells (Th2s), all of which exhibit enriched IL-33R expression.
High levels of IL-33 expression in the CNS were originally re-
ported some 10 years ago (Schmitz et al., 2005), but its cellularexpression pattern, its function as an alarmin, and its actions
on local cells there remain an active area of investigation. Early
studies yielded somewhat conflicting reports on IL-33 regulation
and localization in the CNS. In-vitro-cultured astrocytes express
IL-33, and this expression was greatly potentiated by treatment
with other DAMPs (Hudson et al., 2008; Yasuoka et al., 2011).
Another group, studying IL-33 in the experimental autoimmune
encephalomyelitis (EAE) mouse model of multiple sclerosis, re-
ported IL-33 expression in healthy astrocytes and neurons,
with little change after EAE induction (Jiang et al., 2012). In yet
another study of the regulation of IL-33 expression in the devel-
oping CNS, IL-33 was produced in both developing astrocytes
and oligodendrocyte precursor cells (OPCs) (Wicher et al.,
2013). However, this group did not detect IL-33 expression in
adult animals.
We recently readdressed the question of IL-33 expression in
the healthy adult CNS by first measuring IL-33 mRNA in several
different tissues and brain regions (Gadani et al., 2015). A strong
correlation was identified betweenmyelination and IL-33 content
among brain regions, which ultimately reflected enriched
expression of IL-33 in CC1+ oligodendrocytes. IL-33 was also
generally expressed by astrocytes in gray matter but not in white
matter. In contrast, IL-33 expression was not detectable in mi-
croglia, neurons, or OPCs. Flow cytometric analysis of whole
brain showed that approximately 30% of all brain cells express
IL-33 (Gadani et al., 2015). Furthermore, IL-33 was released by
CNS tissue after injury, becoming detectable in the cerebrospi-
nal fluid after spinal cord contusion and in the supernatant of
in-vitro-damaged spinal cords. Secretion of IL-33 following tis-
sue damage in vitro was not associated with enhanced IL-33
expression, suggesting that its release after CNS damage is
probably not a result of increased IL-33 transcription but rather
the release of endogenously expressed protein (Gadani et al.,
2015).
IL-33 is known to influence inflammation in many peripheral
disease models (Oboki et al., 2010), in sepsis (Jiang et al.,
2012) and in EAE (Jiang et al., 2012; Oboki et al., 2010), but its
role in the post-injury regulation of CNS repair is only now begin-
ning to be elucidated. IL-33 can stimulate CCL2 production by
mixed glia in vitro (Gadani et al., 2015; Kempuraj et al., 2013),
and IL-33/ mice show significantly reduced production of
several chemokines at the injury site after SCI (Gadani et al.,
2015). This defect in chemokine expression was coupled with
reduced recruitment of peripheral monocytes, impaired recov-
ery, and increased lesion volume after SCI and with decreased
neuronal survival after optic nerve crush (Gadani et al., 2015).
Furthermore, exogenous administration of CCL2 into the site of
SCI in IL-33/mice was found to promote recovery, suggesting
that delayed monocyte recruitment underlies increased pathol-
ogy in these animals (Gadani et al., 2015). It is interesting that
IL-33 signaling can also be potentiated to improve outcomes in
wild-type (WT) mice, as intraperitoneal injection of exogenous
IL-33 was found to improve locomotor recovery and reduce
lesion size after SCI (Pomeshchik et al., 2015).
It should be noted that many of the alarmins and DAMPs—
including IL-1a, mtDNA, and uric acid—shown to coordinate
immune responses to peripheral tissue injury have not been
adequately studied in the context of in vivo injury to the CNS.Neuron 87, July 1, 2015 ª2015 Elsevier Inc. 51
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ment of these molecules in the regulation of responses to
CNS injury.
Minutes to Hours after CNS Injury: Inflammasome
Activation, Cytokine Production, and
Neutrophil Recruitment
Cytokine Secretion and the Inflammasome
DAMPs released immediately after injury initiate a cascade of
cellular and molecular immune mediators to amplify inflamma-
tion. Early molecular players in this cascade include cytokines
such as tumor necrosis factor (TNF), IL-6, and IL-1b, which are
upregulated rapidly by local and infiltrating immune cells in
response to DAMPs (Ransohoff and Brown, 2012). These mole-
cules are critical amplifiers of the innate immune response to
CNS injury and represent potential therapeutic targets. For
example, TNF has been identified as a detrimental cytokine, ex-
pressed early after injury by red-blood-cell-engulfing macro-
phages (Kroner et al., 2014). Furthermore, studies blocking early
TNF signaling in vivo show promise in rodent models and
humans to improve outcome after CNS trauma (Esposito and
Cuzzocrea, 2011). Similarly blocking IL-6 signaling promotes re-
covery in rodent spinal cord injury (Mukaino et al., 2010; Okada
et al., 2004).
One of the most potent mechanisms by which DAMPs can
provoke inflammatory signaling is through the activation of in-
flammasome platforms and release of cytokines such as IL-1b.
Inflammasomes are multiprotein complexes that generally
consist of three main components: a cytosolic PRR, the enzyme
caspase-1, and the adaptor protein apoptosis-associated,
speck-like protein containing CARD (ASC) (Lukens and Kanne-
ganti, 2014). Recognition of PAMPs and DAMPs by inflamma-
some-associated PRRs promotes the assembly of inflamma-
some components into a multiprotein complex and culminates
in the secretion of active IL-1b and IL-18. The generation of
mature IL-1b and IL-18 is a coordinated multi-step process,
where the first step requires transcription and translation of pro-
IL-1b and pro-IL-18 and is often initiated by TNF-, IL-1a-, or
TLR-induced activation of NF-kB signaling (Bauernfeind et al.,
2009). The second step requires assembly of the intracellular
PPR, the adaptor protein ASC, and pro-caspase-1. These pro-
teins form the inflammasome complex, which is needed to orient
pro-caspase-1 for autocleavage and activation. Once activated,
caspase-1 cleaves pro-IL-1b and pro-IL-18, providing the final
step required for their secretion and inflammatory signaling
(Figure 2).
Members of the NLR and ALR families, as well as the protein
Pyrin, have all been shown to function as cytoplasmic PRRs
that coordinate inflammasome formation and activation. To
date, a number of NLRs (NLRP1, NLRP3, NLRP6, NLRP7,
NLRP12, and NLRC4) and ALRs (AIM2 and IFI16) have been re-
ported to induce inflammasome activation (Latz et al., 2013;
Lukens and Kanneganti, 2014). These intracellular PPRs can
orchestrate inflammasome signaling in response to a variety of
diverse pathogen- or danger-associated triggers. For example,
the ALRs AIM2 and IFI16 activate the inflammasome in response
to the presence of cytosolic DNA (Fernandes-Alnemri et al.,
2009; Hornung et al., 2009; Roberts et al., 2009), whereas52 Neuron 87, July 1, 2015 ª2015 Elsevier Inc.NLRC4 induces inflammasome signaling following recognition
of bacterial flagellin or type III secretion system-associated bac-
terial proteins (Wang et al., 2011). NLRP3, on the other hand, can
trigger inflammasome formation and activation in response to
both pathogenic and endogenous danger signals (Strowig
et al., 2012). Examples of NLRP3 inflammasome triggers that
are released in response to CNS trauma include ATP, uric acid,
reactive oxygen species, and necrotic cells. It is interesting
that NLRP3 inflammasome-dependent cytokine production
was recently reported to contribute to the pathogenesis of
multiple neuroinflammatory and neurodegenerative disorders,
including multiple sclerosis, Alzheimer’s disease, and amyotro-
phic lateral sclerosis (ALS) (Halle et al., 2008; Lukens et al.,
2012a; Meissner et al., 2010). Inflammasome-associated pro-
teins are highly expressed in the CNS, and inflammasomes
have been reported to assemble in glial cells and neurons (Liu
et al., 2013; Tomura et al., 2012; Walsh et al., 2014a).
Recent studies suggest critical roles for inflammasomes in
promoting CNS tissue damage in models of TBI and SCI (de Riv-
ero Vaccari et al., 2012). In both cases, neutralization of the
NLRP1 and NLRP3 inflammasomes with anti-ASC antibodies
significantly decreased the post-injury pathology (ASC is an
intracellular target, and although that study showed that anti-
ASC antibodies reduce inflammasome activity and enter neu-
rons, it is unclear conceptually how this happens) (de Rivero
Vaccari et al., 2008, 2009). While those authors focused on
and attributed the observed effects to neuronal inflammasomes,
treatment with anti-ASC antibodies should globally disrupt in-
flammasomemobilization in all CNS cells and would also, in the-
ory, affect glial inflammasomes. Therefore, it remains unclear
whether themost potent inflammasome-mediated IL-1b produc-
tion after injury is exhibited by microglia, neurons, or astrocytes.
Those few initial works imply harmful roles for inflammasome
activation in models of CNS injury. Additional studies are
needed, however, to establish how specific inflammasome-
derived cytokines and downstream events, such as pyroptosis,
contribute to overall disease pathogenesis.
Inflammasome activation also has implications for the alarmin
IL-33. This alarmin is a member of the IL-1 cytokine family, along
with IL-1b, IL-1a, and IL-18. Cleavage by caspase-1, in contrast
to its effect on IL-1b and IL-18, inactivates IL-33 (Cayrol and Gir-
ard, 2009). Certain other cleavage forms of IL-33, however, are
more potent than the native form, particularly, the products of
neutrophil elastase and cathepsin G cleavage (Lefranc¸ais
et al., 2012). This makes sense, given the alarmin nature of
IL-33. IL-1b is produced by effector cells and requires multiple
signals to become fully active. IL-33, on the other hand, carries
a rapid message from necrotic cells and, therefore, logically re-
quires no processing to elicit its activity. Furthermore, neutro-
phils generally degranulate at the injury site, secreting enzymes
such as elastase that can cleave native IL-33 to a more active
form and reinforce the effect of its release soon after injury,
before IL-33 can be neutralized by the inflammasome (Lefranc¸ais
et al., 2012).
Innate Immunity: Neutrophils
After most injuries, the first peripheral cells to arrive on the
scene are neutrophils. These are granular cells that are continu-
ously produced in the bone marrow and, after a short life in
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et al., 2010)—are cleared by bone marrow and liver macro-
phages (Shi et al., 2001; Summers et al., 2010). Once mobilized
to a site of irritant-induced tissue damage, neutrophils can exert
potent effector functions that include the rapid release of cyto-
kines, chemokines, lytic enzymes, and growth factors (Summers
et al., 2010). As with other injuries, large numbers of neutrophils
appear at the site of CNS injury as soon as 4 hr after its occur-
rence and remain there for 2–3 days (Carlson et al., 1998; Trivedi
et al., 2006). Numerous factors can promote neutrophil recruit-
ment, including the chemokines KC and MIP2 (CXCL1 and
CXCL2, respectively). A recent study also showed that puriner-
gic-receptor-induced signaling, probably via inflammasome
activity and increased chemokine production, profoundly influ-
ences neutrophil mobilization to sites of CNS injury (Roth et al.,
2014).
Neutrophils are specialists in fighting pathogens, secreting
key anti-microbial products, but their impact on sterile injury
is less clear. Following their extravasation, neutrophils release
large amounts of effector molecules including proteases, cyto-
kines, and free oxygen radicals to combat any invading patho-
gens (Amulic et al., 2012). On neuronal cells, however, these
efforts have nonspecific and harmful effects. Blocking of the
neutrophil-secreted enzyme elastase, indeed, improved recov-
ery of rats after SCI (Tonai et al., 2001). Prevention of neutrophil
migration into injured CNS tissue through inhibition of CXCR2
was found to ameliorate post-injury neuronal loss (Semple
et al., 2010) as well as to promote tissue repair and enhance
functional recovery (Gorio et al., 2007). An alternative method
of preventing neutrophil influx into the injured tissue was based
on knockout of C5, a neutrophil chemotactic component of the
complement cascade; C5/ mice were shown to have a deficit
in neutrophil infiltration into the site of cryoinjury that correlated
with a decrease in lesion size (Sewell et al., 2004). A number of
other studies have linked beneficial pharmacological treatment
to a decrease in initial neutrophil recruitment (Naruo et al.,
2003).
Despite the wealth of supporting evidence, however, it might
be premature to conclude that neutrophils are universally detri-
mental in CNS injury. In one study the authors sought to directly
address the role of neutrophils in SCI by depleting mice of neu-
trophils using a depleting antibody that targeted the neutrophil
surface protein Ly6G/GR-1. These mice showed worse func-
tional hindlimb recovery and delayed astrocyte reactivity, sug-
gesting that neutrophils have a positive effect on the local glial
response (Stirling et al., 2009). An important caveat acknowl-
edged by those authors, however, was the nonspecific nature
of the cell depletion. Neutrophils in the antibody-treated mice
were severely reduced, but both circulating monocytes and lym-
phocytes were also lowered, albeit to a lesser extent (Stirling
et al., 2009). Another study of neutrophil depletion after crush
injury of the mouse optic nerve (this time using a more neutro-
phil-specific Ly6G clone) also demonstrated a beneficial role
for neutrophils, and showed that improved outcome of CNS
injury was associated with their production of the atypical growth
factor oncomodulin (Kurimoto et al., 2013). Given the existing
data, therefore, it remains unclear whether the overall effect of
neutrophils is beneficial or detrimental, and isolated aspectsof their function can have dichotomous effects on outcome
(Figure 3).
Hours to Days Post-CNS Injury: Infiltration of Monocytes
Innate Immunity: Monocyte-Derived Macrophages
Bloodmonocytes can be classified into two types based on their
surface molecule profiles and unique functions: Ly6Chi mono-
cytes, which express the chemokine receptor CCR2 and low
levels of the chemokine receptor CX3CR1, and Ly6Clo mono-
cytes (blood-resident monocytes), which express high levels
of CX3CR1. Ly6Chi monocytes circulate in the blood and are re-
cruited to sites of tissue injury in response to endothelial activa-
tion and chemokine gradients. Monocyte-derived macrophages
(from now on termed just ‘‘macrophages’’ to distinguish them
from microglia and other tissue-resident populations) are prom-
inent cells at injury sites.
Macrophages are generally believed to carry out beneficial
functions such as orchestrating wound-healing responses and
coordinating the removal of debris in models of peripheral tissue
injury. Infiltrating macrophages initially promote inflammation,
but later, they are necessary for its proper resolution, promotion
of angiogenesis, scar formation, and secretion of growth factors
(reviewed in Brancato and Albina, 2011; Koh and DiPietro, 2011;
Werner and Grose, 2003). As expected on the basis of these
functions, ablation of macrophages delays normal peripheral
wound-healing responses in rodents (Mirza et al., 2009; Ram-
sebner et al., 2010) and regeneration of limbs in amphibians
(Godwin et al., 2013). Macrophages are also important to regen-
eration after peripheral nerve injury, where they are robustly re-
cruited by Schwann cells along the injured nerve and play a vital
role in clearing myelin and apoptotic debris (Brosius Lutz and
Barres, 2014; Tofaris et al., 2002; Vargas et al., 2010). The role
of macrophages after CNS injury, however, is more controver-
sial, with studies showing them to be either beneficial (Batchelor
et al., 1999; Gadani et al., 2015; Kotter et al., 2001; London et al.,
2011; Prewitt et al., 1997; Shechter et al., 2009, 2013; Yin et al.,
2006) or harmful (Evans et al., 2014; Horn et al., 2008; McPhail
et al., 2004; Popovich et al., 1999), as discussed in detail in the
next section.
Beneficial versus Destructive Roles of Macrophages in
CNS Injury
After entering the CNS injury site, macrophages have several
functions; some of them have been shown to be beneficial,
and others have been shown to be detrimental (Figure 3). A
well-known neurotoxic product of activated microglia and mac-
rophages is glutamate, a primary CNS excitatory neurotrans-
mitter, which is released in large quantities after injury and
contributes to both neuronal excitotoxicity and secondary
degeneration (Bullock et al., 1995; Doble, 1999; Yawata et al.,
2008). Moreover, TNF—a cytokine robustly produced after
injury—is a major stimulator of microglial production of gluta-
mate and can further potentiate glutamate-induced killing of
neurons (Leonoudakis et al., 2008; Olmos and Llado´, 2014).
Macrophages also contribute to secondary death through the
production of nitric oxide synthase (iNOS) and free radicals.
Free oxygen radicals are abundantly produced at the injury site
and contribute to neuronal death (Lewe´n et al., 2000; Roth
et al., 2014). Expression of iNOS by macrophages andNeuron 87, July 1, 2015 ª2015 Elsevier Inc. 53
Figure 3. Beneficial and Detrimental Roles for Macrophages and Neutrophils in CNS Injury
Macrophages and neutrophils have been described to promote both beneficial and detrimental outcomes following CNS injury. Whether these cells orchestrate
CNS repair or exacerbate tissue damage following CNS trauma depends on the specific factors that are generated. Beneficial roles for macrophages (top left) in
the CNS include their ability to clear cell debris and produce growth factors and other protective molecules, including BDNF, glial cell line-derived neurotrophic
factor (GDNF), and IL-10. Detrimental roles for macrophages (top right) include production of glutamate and contact-mediated axon dieback. Bothmacrophages
and neutrophils beneficially produce the atypical growth factor oncomodulin and clear pathogens in non-sterile injuries (left) and detrimentally produce the free
radical nitric oxide (right). Neutrophils additionally secrete the enzyme elastase, which was shown to be detrimental following injury (right).
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quent production of nitrogen oxide radicals can provoke
neuronal apoptosis (Satake et al., 2000). Studies by Jerry Silver
and colleagues have uncovered direct contacts betweenmacro-
phages and neurons both in vivo and in vitro, which appear to
precede and correlate with axon retraction (Evans et al., 2014;
Horn et al., 2008). The nature of this interaction and its molecular
mediators or purposes is unclear. However, axon retraction
in vivo is markedly reduced by treatment with clodronate lipo-
somes, which kill engulfing phagocytes (Horn et al., 2008).
In addition to the many reports on the detrimental effects of
macrophages, evidence from numerous labs suggests that mac-
rophages also contribute to tissue protection and regeneration
after CNS injury. Macrophages secrete growth-promoting mole-
cules, including neurotrophins and oncomodulin (Dougherty
et al., 2000; Hashimoto et al., 2005; Yin et al., 2006), phagocy-
tose inhibitory myelin debris (Ma et al., 2002), and promote path-
ogen clearance in non-sterile injuries (Shi and Pamer, 2011). One
compelling link between inflammation and axon regrowth is
oncomodulin, an atypical growth factor mentioned earlier as a
neutrophil product. Oncomodulin is a potent factor in promoting
axonal growth and is also produced by inflammatory macro-
phages after CNS injury (Yin et al., 2006). Stimulation of macro-
phages with the TLR2 agonist zymosan increases macrophage
production of oncomodulin, which promotes axon regrowth
in vitro and in vivo through the activation of CaMKII-dependent54 Neuron 87, July 1, 2015 ª2015 Elsevier Inc.signaling (Yin et al., 2006). While its effects have been well stud-
ied in the eye, less is known about the role of oncomodulin in
other CNS injury models such as SCI or TBI.
Shechter et al. (2009) addressed the overall impact of macro-
phages on SCI using two methods: by increasing the pool of
monocytes via adoptive transfer and by depleting myeloid cells
using the CD11cDTR/WT bone marrow chimeric mouse (diph-
theria toxin receptor [DTR] is expressed only on CD11c+ cells,
allowing bloodborne macrophages to be targeted). In both con-
ditions, macrophages proved beneficial; the addition of macro-
phages increased functional recovery, while their ablation with
CD11cDTR exacerbated CNS pathology (Shechter et al., 2009).
A major function identified in that work and ascribed to macro-
phages was production of IL-10, a cytokine that both dampens
and promotes resolution of inflammation (Shechter et al.,
2009). This study supported previously observed beneficial
aspects (mostly reported from the same lab) of boosting macro-
phage numbers after CNS injury (Bomstein et al., 2003; Lazarov-
Spiegler et al., 1998; Rapalino et al., 1998; Schwartz, 2010;
Schwartz et al., 1999; Schwartz and Yoles, 2006).
In one line of experiments spanning numerous studies over
several decades, homologous macrophages were activated
in vitro in co-culture with explanted tissue that typically heals
well (such as skin or peripheral nerve) before they were deliv-
ered directly to the CNS injury site (Schwartz, 2010; Schwartz
and Yoles, 2006). The intention was to add phagocytes
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DAMPs from the skin (or other tissue with efficient healing
properties) to instruct macrophages to become better tissue
healers. This strategy proved beneficial in animal models of
SCI (Schwartz, 2010) and was tested in phase I (Knoller et al.,
2005) and phase II clinical trials (Jones et al., 2010; Lammertse
et al., 2012), although it did not proceed to phase III trials
(Lammertse et al., 2012).
Macrophage Polarization in CNS Injury: Is It Really
that Simple?
Macrophages are heterogeneous immune cells that can be acti-
vated to fight pathogens and promote tissue regeneration (Epel-
man et al., 2014). These functions are often attributed to two
macrophage phenotypes: M1 and M2. These phenotypes and
their respective stimuli have been well described in vitro. M2
macrophages are induced by the cytokines IL-4 and IL-13
and characteristically express the markers arginase 1 (Arg1),
CD206, and YM-1, while M1 macrophages are induced by
IFN-g and LPS and express iNOS, TNF, and CCL5 as markers
(Gordon, 2003; Sica and Mantovani, 2012). As described earlier,
discrete beneficial and detrimental functions after CNS injury
have been defined for macrophages (Figure 3). M1/M2 skewing
is a convenient paradigm for explaining these divergent macro-
phage effects, with M1 products being harmful and M2 products
being beneficial, and numerous studies have been focused on
macrophage skewing and the proportions of M1 versusM2mac-
rophages in the injured CNS (Girard et al., 2013; Kigerl et al.,
2009; Kumar et al., 2013; Stirling et al., 2014; Turtzo et al.,
2014; Wang et al., 2013). However, it is becoming increasingly
evident that, although these paradigms clearly exist under
controlled in vitro settings, they are too simplistic to describe
macrophage phenotypes in vivo (Martinez and Gordon, 2014;
Murray et al., 2014). This is apparent after CNS injury, where
M1 and M2 markers do not appear in discrete groups but are
often expressed simultaneously by inflammatory macrophages.
For example, at early time points after injury (1–3 days), both the
M1 marker Nos2 (the gene that encodes iNOS) and the M2
marker Arg1 (the gene encoding Arg1) are upregulated at the
injury site (Kigerl et al., 2009). In another study by Hsieh et al.
(2013), Arg1-positive cells were isolated frommice and analyzed
by microarray analysis on day 3 post-TBI. They found, notably,
that Arg1-positive cells, although assumed to be M2, do not ex-
press many other M2 markers and actually express multiple M1
markers (including nos2, consistent with the aforementioned
findings of Kigerl et al.) (Hsieh et al., 2013). These findings are
not altogether surprising, as it is known that macrophage polar-
ization is not stringently defined in vivo (Martinez and Gordon,
2014). Macrophages can exhibit simultaneous expression of
M1 and M2 markers and may be able, given appropriate stimuli,
to switch phenotypes (Pettersen et al., 2011; Sica and Manto-
vani, 2012; Vogel et al., 2013).
Under normal physiological conditions, macrophage subsets
in the body are heterogeneous (Ginhoux et al., 2010), and individ-
ual characteristics are imparted by tissue-specific signals
(Butovsky et al., 2014; Okabe and Medzhitov, 2014). It is likely
that similar heterogeneity in the macrophage population also
develops after CNS injuries and that, under those conditions,
the unique infiltrating macrophage phenotype is influenced bya myriad of extracellular and inflammatory signals that ensue
as a result of CNS tissue damage.
In summary, M1/M2 classifications, as they exist under in vitro
conditions, do not appear to apply neatly to macrophages after
CNS injury, and recent findings highlight the diversity of macro-
phage phenotypes that can arise from different stimulations (Xue
et al., 2014). Therefore, it seems that, rather than trying to fit
CNS-infiltrating macrophages into categories that are largely
based on responses to isolated stimuli in vitro, efforts would
be better spent in attempting to understand the unique subset(s)
existing at the CNS injury site. These subsets can probably not
be defined simply as ‘‘inflammatory’’ (M1) and ‘‘anti-inflamma-
tory’’ (M2) but rather by unique, nuanced sets of functions and
markers that are dependent on complex temporal, spatial, and
signaling factors.
The ultimate role of macrophages in any sterile injury, and
particularly in CNS injury, is an area of active investigation. Mac-
rophages have been reported to perform both beneficial and
detrimental functions in response to CNS trauma, but the degree
of impairment caused by their depletion suggests that their over-
all role is protective (Gadani et al., 2015; Shechter et al., 2009).
Improved characterization of the discrete macrophage pheno-
types that arise in response to CNS injury will help to uncover
the specific molecular pathways that promote beneficial macro-
phage responses during trauma and can be expected to aid in
the development of novel macrophage-based therapies for the
treatment of CNS injury.
Days to Weeks Post-CNS Injury: Recruitment of
Adaptive Immune Cells
As with macrophages and neutrophils, the beneficial or detri-
mental nature of the adaptive immune system in CNS injury is
a hazy picture that is slowly becoming better defined. Partly
based on early dogma in the field of CNS injury, adaptive immune
responses to the injury were assumed to be largely detrimental
by default (Hickey et al., 1991; Popovich et al., 1996). Strikingly,
however, secondary degeneration is more extensive in rodents
that lack both T and B cells than in their WT counterparts (Moa-
lem et al., 1999; Serpe et al., 1999; Yoles et al., 2001), suggesting
a previously unknown neuroprotective role for adaptive immune
cells in CNS injury. In immunodeficient (severe combined immu-
nodeficiency [SCID] or nude) mice, reconstitution of the immune
compartment with T cells was found to improve recovery from
CNS injury (Kipnis et al., 2002; Serpe et al., 2003), further sug-
gesting that T cells have a role to play in neuroprotection. It is
interesting that T cells specific to brain-restricted antigens
were found to be particularly potent in promoting neuroprotec-
tion (Moalem et al., 1999), and it seemed that their migration to
the injured CNS and their accumulation there were most prob-
ably governed by their CNS-antigen specificity (Archambault
et al., 2005; Ling et al., 2006). Transfer of autoreactive T cells
directed against CNS antigens, indeed, substantially reduced
secondary degeneration after nerve injury in rats, and this neuro-
protection could be conferred either by active immunization (with
spinal cord homogenates or purified myelin proteins and adju-
vant) or by passive immunization (via the transfer of pre-acti-
vated CNS-specific T cells) (Byram et al., 2004; Hauben et al.,
2000; Moalem et al., 1999). However, antigen specificity is notNeuron 87, July 1, 2015 ª2015 Elsevier Inc. 55
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our recent studies have shown that T cells can endow appre-
ciable neuroprotection after CNS injury, even in the absence of
antigen recognition (Walsh et al., 2015).
In the adaptive immune system, pattern recognition has been
largely overlooked, despite the fact that it plays an important
part in the function of lymphocytes not only by affecting cellular
migration and activation but also through modulation of their ac-
tivity (Iwasaki and Medzhitov, 2010; Pasare and Medzhitov,
2004). Studies have identified PRRs on CD4+ T cells and pointed
to TLR signaling as an important player in CD4+ T-cell-mediated
neuroprotection through its activity on regulatory T cells (Pasare
and Medzhitov, 2003). One of the major mechanisms underlying
PRR-induced activation of immune cells is induction of MyD88-
mediated signaling. We recently observed that production of the
neuroprotective cytokine IL-4 by CD4+ T cells in response to
CNS injury is not dependent on classical T cell receptor/MHC II
engagement but is critically dependent on MyD88-mediated
signaling (Walsh et al., 2015). These findings point to pivotal roles
for PRR-triggered activation of MyD88 signaling in the generation
of neuroprotective T-cell responses, although the specific PRR
ligands that mediate this effect still remain to be elucidated. IL-4
production by injury-induced T cells was shown to promote
CNS recovery downstreamof this activation by acting on neurons
directly, not via IL-4 signaling inmacrophages (Walsh et al., 2015).
Conclusion
How the immune system responds to CNS injury remains a
matter of debate, and there is still no general consensus as to
whether it is mainly deleterious or beneficial. The notion that
peripheral immunity causes only damage to the CNS is still
prevalent and is supported by the early relative success of
the immunosuppressive drug methylprednisone in the treatment
of CNS injury and the recognition that inflammation underlies
the pathology of the autoimmune disease multiple sclerosis
(Steinman et al., 2002). However, as described in this review,
multiple lines of evidence from various models of CNS trauma
now clearly demonstrate that immune cells can also have
beneficial functions in the CNS. Moreover, emerging data
suggest that there is extensive crosstalk between the immune
system and glial cells, even in the absence of overt CNS immu-
nopathology. The concept of immune privilege was derived
from early studies demonstrating that rejection of engrafted
tissue is delayed in the brain and should not be interpreted to
preclude beneficial neuroimmune interactions, either in the
healthy CNS or after injury. Inflammatory cells clearly have
both beneficial and detrimental functions after CNS injury, but
it appears that the overall effect of immune-cell subtypes on
injury, as assessed by depletion or knockout studies, is generally
beneficial.
This review surveys the progress of research carried out over
the past 2 decades on the immune response to CNS injury, start-
ing with the seminal discoveries in connection with DAMPs and
the initiation of inflammation and progressing through subse-
quent cell infiltration events. With regard to the specific events
that occur in CNS injury, we note that the response of the im-
mune system to brain injury does not differ substantially from
its response to injury of any peripheral tissue.56 Neuron 87, July 1, 2015 ª2015 Elsevier Inc.Countries charge their military with two vital assignments: to
destroy hostile groups invading their borders and to aid their cit-
izens when the need arises to cope, for example, with natural di-
sasters. We view the immune system as functioning in much the
same way; it defends the organism against dangerous invading
pathogens while also helping to protect it from the devastating
effects of sterile injuries. Deeper understanding of DAMPs in
the CNS will shed light on the pathologies associated with its
injury as well as on a host of neurodegenerative syndromes
associated with sterile inflammation, such as Alzheimer’s dis-
ease (Rubio-Perez and Morillas-Ruiz, 2012), ALS (Frakes et al.,
2014), autism spectrum disorder (Patterson, 2011), and epilepsy
(Marchi et al., 2014). Further understanding of the initiation of
inflammation will enable us to design more effective therapies
for timely, beneficial modulation of the immune response.
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